Brevan Howard Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Brevan Howard Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,117	Closed	-$405K	–	2132
2025 Q4	$405K	Sell	16,117 -74,904	-82%	-$1.76M	﹤0.01%	1208
2025 Q3	$2.06M	Buy	+91,021	New	+$2.12M	0.01%	545
2024 Q4	–	Sell	-19,928	Closed	-$575K	–	1028
2024 Q3	$575K	Buy	+19,928	New	+$738K	﹤0.01%	647
2024 Q2	–	Sell	-10,415	Closed	-$612K	–	1052
2024 Q1	$612K	Buy	10,415 +6,072	+140%	+$387K	0.01%	394
2023 Q4	$260K	Buy	+4,343	New	+$220K	﹤0.01%	784
2023 Q3	–	Sell	-2,276	Closed	-$207K	–	388
2023 Q2	$207K	Buy	+2,276	New	+$196K	﹤0.01%	180

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Brevan Howard Capital Management's APLS Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 16,117 shares — an estimated $405K sold.

Brevan Howard Capital Management first reported a position in APLS in Q2 2023 and held it in 6 quarters. The position peaked at $2.06M in Q3 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Brevan Howard Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 16,117 Apellis Pharmaceuticals shares in Q1 2026, an estimated $405K.
Brevan Howard Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Brevan Howard Capital Management's Apellis Pharmaceuticals position peaked at $2.06M in Q3 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.